Fosamax-Related Osteonecrosis of the Jaw: Biological Plausibility Explained

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

General Health Context and Medication Safety

The legacy of general health and science information has long served as a foundation for public understanding of medical risks and preventive care. Within this broad context, discussions of medication safety and adverse effects have traditionally focused on systemic outcomes, such as gastrointestinal or cardiovascular complications. This heritage emphasizes the importance of informed patient consent and the role of healthcare providers in communicating potential harms associated with therapeutic interventions. Transitioning from this general framework to a more specific occupational exposure concern requires a shift in perspective. While the general health context addresses patient-level risks from prescribed medications, occupational settings introduce distinct variables, including prolonged or repeated exposure to pharmaceutical agents during manufacturing, handling, or disposal. In such environments, workers may encounter higher concentrations or different routes of exposure than typical patients, necessitating a focused evaluation of potential health impacts. This pivot from general health information to occupational exposure concern is particularly relevant when considering medications with known biological activity in bone metabolism. The transition highlights how a substance’s mechanism of action, originally studied in a therapeutic context, may pose unique risks in occupational settings where exposure patterns differ. Thus, the bridge concept moves from broad patient education to a targeted assessment of workplace safety, maintaining a neutral academic tone while acknowledging the need for specialized risk communication in industrial hygiene.

Bridging to Occupational Exposure Concerns

The transition from general health information to occupational exposure concern is particularly relevant when considering medications with known biological activity in bone metabolism. The transition highlights how a substance’s mechanism of action, originally studied in a therapeutic context, may pose unique risks in occupational settings where exposure patterns differ. Thus, the bridge concept moves from broad patient education to a targeted assessment of workplace safety, maintaining a neutral academic tone while acknowledging the need for specialized risk communication in industrial hygiene.

Fosamax and Osteonecrosis of the Jaw: Mechanistic Pathways

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with osteonecrosis of the jaw (ONJ), a condition characterized by exposed, non-healing bone in the maxillofacial region. The biological plausibility of this association is supported by mechanistic pathways, clinical presentation, and documented risk factors. Osteonecrosis of the jaw can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The mechanistic pathways linking Fosamax to ONJ involve the drug's pharmacological action on bone remodeling. Bisphosphonates like alendronate inhibit osteoclast-mediated bone resorption, which reduces bone turnover. In the jawbone, which has a high rate of remodeling due to constant mechanical stress from chewing and the presence of teeth, this suppression can lead to microdamage accumulation and impaired healing. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents has provided comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). Studies in estrogen-deficient rats treated with alendronate have examined effects on the jawbone, including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077). These findings suggest that bisphosphonate treatment alters the mechanical and structural properties of the jawbone, potentially predisposing it to necrosis.

Clinical Presentation and Diagnosis of ONJ

The clinical presentation of ONJ includes exposed bone in the oral cavity that persists for more than eight weeks, often accompanied by pain, swelling, infection, and delayed healing after dental procedures. Diagnosis is primarily clinical, based on visual examination and history of bisphosphonate use. The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Warnings and Causation Considerations

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under warnings and precautions. It states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for patients at low-risk for fracture, drug discontinuation after 3 to 5 years of use is considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Causation considerations for affected patients involve establishing a temporal relationship between Fosamax exposure and the development of ONJ, excluding other potential causes such as cancer, radiation therapy, or other medications. The timeline between exposure and documented harm can range from days to months after starting the drug, and the risk may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Patients who develop ONJ while on Fosamax should discontinue the drug if severe symptoms develop, and management includes conservative measures such as oral rinses, antibiotics, and avoidance of invasive dental procedures.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the biological plausibility of Fosamax causing osteonecrosis of the jaw?

Fosamax (alendronate) inhibits osteoclast-mediated bone resorption, reducing bone turnover. In the jawbone, which undergoes high remodeling, this suppression can lead to microdamage accumulation and impaired healing, predisposing to necrosis. Preclinical studies have shown altered mechanical and structural properties of jawbone in alendronate-treated rats (https://pubmed.ncbi.nlm.nih.gov/40345077).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures. Duration of bisphosphonate use also increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.